Ionis Pharmaceuticals, Inc. (0JDI)
Summary
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
Ionis Pharmaceuticals, Inc. (0JDI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ionis Pharmaceuticals, Inc. ever had a stock split?
Ionis Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brett Monia CEO | LSE Exchange | 462222100 CUSIP |
| US Country | 1,402 Employees | 17 Feb 2000 Last Dividend | - Last Split | 17 May 1991 IPO Date |
Overview
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of RNA-targeted therapeutics. Based in Carlsbad, California, the company has pioneered advances in drug discovery, particularly in the development of antisense therapies that modulate gene expression. Ionis Pharmaceuticals targets a wide range of diseases with a significant unmet medical need, including neurological disorders, cardiovascular diseases, and various rare diseases. Since its incorporation in 1989, Ionis has formed strategic collaborations with numerous leading biopharmaceutical companies, including Biogen, AstraZeneca, Bayer AG, GlaxoSmithKline plc, and several others, to advance its mission of delivering groundbreaking therapies to patients worldwide.
Products and Services
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy (SMA) in both pediatric and adult patients. This product demonstrates Ionis’ commitment to addressing neurological disorders with advanced RNA-targeted treatments.
- TEGSEDI: An antisense injection designed for the treatment of polyneuropathy in adults caused by hereditary transthyretin amyloidosis. This product highlights Ionis’ innovative approach to treating rare diseases through genetic modulation.
- WAYLIVRA: An antisense medicine for patients with familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy, showcasing Ionis’ capability in tackling lipid disorders.
- Eplontersen: Currently in phase 3 study, Eplontersen is being developed as a treatment for all types of ATTR (transthyretin amyloidosis) through monthly self-administered subcutaneous injections, reflecting Ionis’ progression in self-care therapeutic solutions.
- Olezarsen: In development for patients with FCS and severe hypertriglyceridemia (SHTG), Olezarsen represents Ionis’ ongoing efforts to combat severe lipid disorders.
- Donidalorsen: Aimed at patients with hereditary angioedema, this candidate signifies Ionis’ investment in developing treatments for rare hereditary disorders.
- ION363: Focused on treating patients with amyotrophic lateral sclerosis, ION363 underscores the company’s dedication to addressing debilitating neurological conditions.
- Tofersen: Aimed to inhibit the production of superoxide dismutase 1, a key factor in certain neurological diseases, demonstrating Ionis’ focus on molecular level interventions.
- Pelacarsen: Targeting established cardiovascular disease and elevated lipoprotein(a) levels, highlighting Ionis’ efforts towards cardiovascular health solutions.
- Bepirovirsen: In development to inhibit the production of viral proteins associated with hepatitis B, showcasing Ionis’ venture into antiviral therapies.
- Other notable developments include IONIS-FB-LRx, to inhibit complement factor B and address the alternative complement pathway, and ION224, aimed at reducing the production of diacylglycerol acyltransferase 2, further illustrating the breadth of Ionis’ therapeutic ambitions.
